Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Consensus Target Price of $6.40 According to Brokerages

Key Points

• Analysts are moderately bullish: Seven firms give Milestone Pharmaceuticals a consensus “Moderate Buy” rating, with an average 12-month price target of $6.40.
• The stock trades well below that target: MIST opened at $0.74, versus a 52-week range of $0.63 to $3.06; institutional investors and hedge funds own 86.18% of shares.
• Recent results missed expectations: Milestone reported a quarterly loss of $0.21 per share against estimates of $0.20 and revenue of $0.56 million versus expectations of $0.82 million.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $6.40.

A number of analysts have recently issued reports on MIST shares. Zacks Research raised shares of Milestone Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Cantor Fitzgerald initiated coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an "overweight" rating and a $3.00 price objective on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Finally, HC Wainwright reiterated a "buy" rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently modified their holdings of MIST. RVW Wealth LLC purchased a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $994,000. Guardian Wealth Advisors LLC NC grew its stake in Milestone Pharmaceuticals by 21.1% in the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company's stock valued at $455,000 after purchasing an additional 59,200 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Milestone Pharmaceuticals in the 1st quarter worth about $397,000. TRU Independence Asset Management 2 LLC acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $201,000. Finally, Renaissance Technologies LLC acquired a new position in Milestone Pharmaceuticals in the 1st quarter worth about $154,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Down 3.3%

NASDAQ:MIST opened at $0.74 on Tuesday. The business's fifty day moving average price is $0.85 and its 200 day moving average price is $1.34. The firm has a market capitalization of $91.88 million, a price-to-earnings ratio of -1.07 and a beta of 1.07. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $0.56 million during the quarter, compared to analysts' expectations of $0.82 million. On average, sell-side analysts forecast that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company's research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders.

Milestone's lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.